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ABSTRACT 
Objective: Ebola virus (EBOV) is an extremely pathogenic, that can cause severe hemorrhagic fever in human with case fatality rates of up to 90% 
for which no vaccine or treatment is currently available. The mechanism underlying this lethal outcome is still unclear. However, an alteration of the 
immune responses represents one of the most important pathogenic mechanisms of Ebola virus infection. EBOV encodes two different proteins 
(VP24 and VP35) that block the induction of immune responses. Thus, we explored the potential interaction of Ebola virus proteins (VP24 and 
VP35) with the Toll-like receptor and MHC-1 receptor.  
Methods: The interaction of Ebola virus protein towards immune system has been checked by Cluspro 2.0.  
Results: Our results indicated that the Ebola Virus proteins (VP 24 and VP 35) have good interaction towards the Toll-like receptor (TLR-3) and 
MHC-1 which are a crucial component of innate and adaptive immune system. 
Conclusion: The findings of this study will be helpful for researchers to design drugs or vaccines for the treatment/prevention of EBOV infections. 
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Ebola virus (EBOV) is belonging to "Filoviridae" family of negative-
sense RNA viruses. It can cause severe hemorrhagic fever leading up to 
90% lethality [1]. This virus is first recognized near the Ebola River 
valley during an outbreak in Zaire in 1976 [2-4]. In the year of 2014, 
Ebola epidemic was the largest in the history that affected people in 
many West African countries. The lethal cases of EBOV infections show 
signs of an impaired innate and adaptive immune response [5, 6].  
The innate immune system utilizes conserved receptor system as a 
sensor of foreign microbial components as well as products of 
damaged or inflamed self-tissues. Examples of such a receptor system 
include toll-like receptors (TLRs), NOD-like receptors (NLRs) and RIG-
1 like receptors (RLRs). TLRs are widely expressed in many cell types 
such as macrophages, neutrophils and dendritic cells [7, 8]. Viruses are 
mainly recognized by TLR3 which results in the MyD88-independent 
activation of IRF3, a key transcription factor necessary for interferon 
production, which leads to the destruction of viruses. In many of the 
viral infections, an early action of cytokines produced by infected cells 
and dendritic cells is not sufficient to eliminate the pathogen [9]. In 
such instances, an adaptive immune response is activated to ensure 
host survival. Recently, Xu et al., 2014 demonstrated that Ebola virus 
proteins (VP 24 and VP 35) actively antagonize STAT1 signaling to 
counteract the antiviral effects of interferons [10]. 
Major histocompatibility complex (MHC) class I molecules are found 
on nearly every nucleated cell of the body. MHC can display peptide 
fragments of viral proteins to the cytotoxic T cells. Therefore, the 
cytotoxic T cells eliminate the viral infected cells by the selections of 
various cytokines. Unfortunately, there are many viruses which 
evolved the various proteins that can interfere with this process and 
results in the failure of adaptive immunity. The Ebola virus is the 
one of them, which produces two major viral proteins (VP 24 and VP 
35) which can inhibit the MHC recognition process. 
Literature has shown that EBOV alters both the innate and adaptive 
immune response signaling pathways through an unknown mechanism 
[5]. Thus, the present investigation has been explored an interaction of 
Ebola viral proteins (VP24 and VP 35) with TLRs and MHC-1.  
To investigate the interaction of Ebola viral proteins (VP24 and VP 35), 
computational analysis was carried out on a Red Hat 5.0, Linux 
platform running on a Dell Precision workstation with Intel core 2 
quad processor and 8 GB of RAM. The x-ray crystal structure of Ebola 
viral VP 35 (PDB: 3L2A) and VP 24 (PDB: 4M0Q) with resolution 
1.71 A˚, 1.92 A˚, 𝑅-value: 0.173 (obs.), 0.211 (obs.);  human toll like 
 receptor (PDB: 1ZIW) and MHC-1 (PDB: 3AM8) wit h resolution  2.10 
A˚, 1.71 A˚, R value:0.210, 0.191 (obs) respectively,were obtained from 
the protein data bank (Research Collaboratory for Structural 
Bioinformatics(RCSB) http://www.rcsb.org/pdb).The proteins 
(PDB:4M0Q, 3L2A, 3AM8 and IZ1W) were prepared by using the 
Protein Preparation Wizard (Shcrodingers LLC). The chain A of all 
proteins were selected for the protein-protein docking protocol using 
Cluspro 2.0. Among the results obtained from Cluspro 2.0, the docked 
protein models with lowest energy with higher number of clusterings 
were selected to study the protein-protein interactions with help of 
Shcrodingers LLC. 
The TLR binding site contains the important residues Asp 36, Ser 38, 
Asp 81, Asp 153, Glu 175, Lys 201, Asn 252, Tyr 383, His 359 and Glu 
434. The docking of Ebola virus VP35 protein (Lys 323, Arg 301, Arg 
311, Lys 271, Glu 251, Tyr 207, Asn 243 and Asp 246) showed good 
interactions with the amino acid of Toll-like receptor as shown in fig. 1.  
 
 
Fig. 1: Interaction of Ebola virus (VP35) with toll-like receptor 
 
The different amino acids of Ebola virus VP35 (Asp 278, Asn 243, Glu 
251, Asp 246,Gln 283, Glu253 and Asp 219) also showed good 
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interaction towards MHC 1 receptor amino acid residues (Arg 17, Arg 
21,Asp 119, Thr 94,Gln96,Arg 48,Arg 35,Arg 48,Tyr 27 and Arg 234) as 
shown in fig. 2. 
 
Fig. 2: Interaction of Ebola virus (VP35) with MHC-1 
 
Ebola virus VP24 binds with ten different amino acid residues (Glu 203,  
Asn 253, Ser 205, Ser 282, Lys 330, Lys 416, Arg 484, Lys 619, Arg 
643 and Asn 662) of the toll-like receptor as shown in fig. 3.  
 
Fig. 3: Interaction of Ebola virus (VP24) with toll-like receptor 
 
In case of MHC-1, ebola virus VP 24 protein interacts with four different 
residues (Glu 232, Glu 229, Arg 48 and Glu 237) as shown in fig. 4. 
 
Fig. 4: Interaction of Ebola virus (VP24) with MHC-1 
In conclusion, these results demonstrated that Ebola virus proteins 
(VP35 and VP24) have a good binding affinity towards human Toll-
like receptor and MHC-1, which plays a key role in innate and 
adaptive immunity. 
ACKNOWLEDGEMENT 
The author acknowledges UGC for financial support in the form of 
Maulana Azad fellowship (MANF-2012-13-CHR-KER-13883). The 
author would like to acknowledge Department of Pharmaceutical 
Sciences and Technology, BIT, Mesra for providing necessary 
facilities to carry out this study.  
CONFLICT OF INTERESTS 
Author declares no conflict of Interest 
REFERENCES  
1. Wang Y, Liu Z, Dai Q. A highly immunogenic fragment derived 
from Zaire Ebola virus glycoprotein elicits effective 
neutralizing antibody. Virus Res 2014;189:254–61. 
2. Bowen ETW, Lloyd G, Harris WJ, Platt GS, Baskerville A, Vella 
EE. Viral haemorrhagic fever in southern Sudan and northern 
Zaire: preliminary studies on the aetiological agent. Lancet 
1977;309:571-3. 
3. Johnson KM, Lange JV, Webb PA, Murphy 
FA. Isolation and partial characterisation of a new virus causing 
acute haemorrhagic fever in Zaire. Lancet 1977;309:569-71. 
4. Peters CJ, Khan AS. Filovirus diseases. Curr Top Microbiol 
Immunol 1999;235:85–95. 
5. Kumar A. Ebola virus is altered innate and adaptive immune 
response signalling pathways: 
Implications for novel therapeutic approaches. Infect Disord-
Drug Targets 2016. Doi:10.2174/18715265166661601081146
44. [Article in Press] 
6. Hoenen T, Groseth A, Falzarano D, Feldmann H. Ebola virus: 
unraveling pathogenesis to combat a deadly disease. 
Trends Mol Med 2006;12:206-15. 
7. Aderem A, Underhill DM. Mechanisms of phagocytosis in macro
phages. Annu Rev Immunol 1999;17:593-623. 
8. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of 
double-stranded RNA and activation of NF-kappaB by toll-like 
receptor 3. Nature 2001;413:732–8. 
9. Kumar A, Sharma N, Singh S, Sasmal D, Dev A. Oral vaccine 
antigen-induced immune response signalling pathways: 
current and future perspectives. J Vac Vaccination 2014;5:2-6. 
10. Xu W, Edwards MR, Borek DM, Feagins AR, Mittal A, Alinger JB, 
et al. Ebola virus VP24 targets a unique NLS binding site on 
karyopherin alpha 5 to selectively compete with nuclear 
import of phosphorylated STAT1. Cell Host Microbe 
2014;16:187–200. 
 
